[go: up one dir, main page]

WO2003066806A3 - Utilisation therapeutique de composes aziridino - Google Patents

Utilisation therapeutique de composes aziridino Download PDF

Info

Publication number
WO2003066806A3
WO2003066806A3 PCT/US2002/035501 US0235501W WO03066806A3 WO 2003066806 A3 WO2003066806 A3 WO 2003066806A3 US 0235501 W US0235501 W US 0235501W WO 03066806 A3 WO03066806 A3 WO 03066806A3
Authority
WO
WIPO (PCT)
Prior art keywords
aziridino compounds
therapeutic use
aziridino
compounds
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/035501
Other languages
English (en)
Other versions
WO2003066806A2 (fr
Inventor
John Chapman
Bernadette Alford
Andrei A Purmal
Boris Zavizion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VI Technologies Inc
Original Assignee
VI Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2001/049956 external-priority patent/WO2002055095A2/fr
Application filed by VI Technologies Inc filed Critical VI Technologies Inc
Priority to AU2002366446A priority Critical patent/AU2002366446A1/en
Priority to CA002466251A priority patent/CA2466251A1/fr
Priority to EP02806003A priority patent/EP1451308A4/fr
Priority to JP2003566157A priority patent/JP2005517023A/ja
Publication of WO2003066806A2 publication Critical patent/WO2003066806A2/fr
Publication of WO2003066806A3 publication Critical patent/WO2003066806A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés de traitement de maladies. Ces procédés consistent à prévenir ou à inhiber la transcription et/ou la réplication de molécule d'acide nucléique par administration à un sujet nécessitant un tel traitement d'une dose efficace d'un ou de plusieurs composés aziridino. L'invention concerne également des compositions pharmaceutiques comprenant le ou les composés aziridino.
PCT/US2002/035501 2001-11-06 2002-11-05 Utilisation therapeutique de composes aziridino Ceased WO2003066806A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002366446A AU2002366446A1 (en) 2001-11-06 2002-11-05 Therapeutic use of aziridino compounds
CA002466251A CA2466251A1 (fr) 2001-11-06 2002-11-05 Utilisation therapeutique de composes aziridino
EP02806003A EP1451308A4 (fr) 2001-11-06 2002-11-05 Utilisation therapeutique de composes aziridino
JP2003566157A JP2005517023A (ja) 2001-11-06 2002-11-05 アジリジン化合物の治療的使用

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
USPCT/US01/49956 2001-11-06
PCT/US2001/049956 WO2002055095A2 (fr) 2000-11-06 2001-11-06 Procedes et reactifs pour therapie immunomodulatrice extracorporelle
US36564802P 2002-03-18 2002-03-18
US60/365,648 2002-03-18
US37918802P 2002-05-09 2002-05-09
US60/379,188 2002-05-09

Publications (2)

Publication Number Publication Date
WO2003066806A2 WO2003066806A2 (fr) 2003-08-14
WO2003066806A3 true WO2003066806A3 (fr) 2003-12-24

Family

ID=27738963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035501 Ceased WO2003066806A2 (fr) 2001-11-06 2002-11-05 Utilisation therapeutique de composes aziridino

Country Status (5)

Country Link
EP (1) EP1451308A4 (fr)
JP (1) JP2005517023A (fr)
AU (1) AU2002366446A1 (fr)
CA (1) CA2466251A1 (fr)
WO (1) WO2003066806A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
US9040507B2 (en) 2008-06-02 2015-05-26 Novelmed Therapeutics, Inc. Method for treating inflammatory conditions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0419890A3 (en) * 1989-09-29 1991-05-29 American Cyanamid Company Stable pharmaceutical formulations for antineoplastic compounds having more than one ethyleneimine group, and method
US6114108A (en) * 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids
AU2002243363A1 (en) * 2000-11-06 2002-07-24 V.I. Technologies, Inc. Use of aziridino-compounds in the treatment of immune dysfunctions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1451308A4 *

Also Published As

Publication number Publication date
JP2005517023A (ja) 2005-06-09
CA2466251A1 (fr) 2003-08-14
EP1451308A4 (fr) 2004-11-17
WO2003066806A2 (fr) 2003-08-14
AU2002366446A1 (en) 2003-09-02
EP1451308A2 (fr) 2004-09-01

Similar Documents

Publication Publication Date Title
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
WO2002042462A3 (fr) Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
WO2001090091A8 (fr) Inhibiteurs de 11-beta-hydroxy-steroide-deshydrogenase de type 1
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
WO2008022256A3 (fr) Procédés et compositions de prévention ou de traitement de maladies liées au vieillissement
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL157656A (en) Metalloproteinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of diseases mediated by metalloproteinase enzymes
NO340679B1 (no) Pyridazinonderivativer, farmasøytiske preparater omfattende slike og slike forbindelser og preparater for anvendelse i terapeutisk aktive substanser til behandling og forebygging av sykdommer
CA2427227A1 (fr) Compose de lactam
WO2004055006A8 (fr) Nouveaux composes presentant un effet inhibiteur selectif de la gsk3
WO2003030934A3 (fr) Formulations cpg et procedes y relatifs
WO2005037798A3 (fr) Nouveaux composés
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
WO2002040702A3 (fr) Methodes de traitement du cancer et d'autres maladies et procedes permettant de developper ces methodes
BRPI0410049A (pt) composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico
WO2005014572A8 (fr) Derives de pyrimidylpyrrole pouvant etre utilises comme inhibiteurs de kinases
WO2004100893A3 (fr) Methodes de traitement d'affections inflammatoires a l'aide de ct-3 ou de ses analogues
WO2007062093A3 (fr) Polytherapie pour le traitement du cancer
MY148125A (en) Compounds
CA2433833A1 (fr) Utilisation de flumazenil dans l'elaboration d'un medicament visant a traiter la dependence a l'alcool
WO2004014367A3 (fr) Immunisation anti-amyloide et inhibiteurs de cox-2 utilises dans le traitement de la maladie d'alzheimer
WO2004073615A3 (fr) Composes de deazaflavine et leurs methodes d'utilisation
WO2001062799A3 (fr) Inhibition de l'angiogenese au moyen de molecules qui ameliorent la formation de plasmine ou prolongent l'activite plasminique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2466251

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002366446

Country of ref document: AU

Ref document number: 2003566157

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002806003

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002806003

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002806003

Country of ref document: EP